Alnylam v. Pfizer: Final Judgment of Noninfringement in LNP Patent Dispute
Alnylam Pharmaceuticals filed suit against Pfizer and Pharmacia & Upjohn in Delaware District Court asserting four patents covering biodegradable lipid nanoparticle delivery technology. After 796 days of litigation, the court entered final judgment of noninfringement on all asserted claims, granting Pfizer’s summary judgment motion on ‘cationic lipid’ claim construction grounds.
Cationic lipid claim construction sinks Alnylam’s LNP infringement case
Alnylam Pharmaceuticals filed this infringement action on May 26, 2023 in the District of Delaware before Judge Colm F. Connolly, asserting four patents — US11590229B2, US11633479B, US11612657B2, and US11633480B2 — all directed to biodegradable lipid compositions used in lipid nanoparticle (LNP) delivery systems. The defendants, Pfizer Inc. and Pharmacia & Upjohn Company LLC, are among the leading commercial developers of LNP-based therapeutics, most notably mRNA vaccine and drug formulations relying on proprietary lipid systems.
The case resolved on July 30, 2025, when the court entered final judgment of noninfringement across all asserted claims of all four patents-in-suit. The critical turning point was the court’s April 28, 2025 denial of Alnylam’s O2 Micro motion seeking resolution of a claim construction dispute over the ‘cationic lipid’ limitations — a ruling that left Pfizer’s summary judgment motion on noninfringement of those limitations unopposed. Alnylam subsequently filed a notice of non-opposition, and the parties stipulated to entry of final judgment. Defendants’ affirmative defenses and counterclaims were dismissed without prejudice, preserving Pfizer’s right to reassert invalidity arguments in future proceedings.
A 796-day duration is broadly consistent with complex pharmaceutical patent disputes in Delaware, though the outcome was driven less by trial and more by a pivotal claim construction ruling. The public record does not disclose whether any licensing discussions occurred or whether the non-opposition to summary judgment reflected a strategic concession to preserve appellate options or conserve litigation spend. The dismissal of counterclaims without prejudice suggests Pfizer retains the ability to challenge patent validity in a future action or inter partes review, meaning the broader IP dispute over LNP cationic lipid technology may not be fully resolved.
Filing to Judgment on the merits for Defendant in 796 days
796-day case — above average for a district court patent infringement action
Final judgment of noninfringement: what the ruling means for both parties
Summary judgment on cationic lipid limitations — how it ended
The case turned on claim construction of ‘cationic lipid’ limitations across all four asserted patents. After the court denied Alnylam’s O2 Micro motion to resolve the construction dispute, Alnylam filed a notice of non-opposition to Pfizer’s pending summary judgment motion. The parties then stipulated to entry of final judgment of noninfringement, a procedural path that avoids a contested ruling but constitutes a binding, final, and appealable judgment on the merits.
Judgment on the meritsAlnylam loses enforcement — appeal rights preserved
Final judgment of noninfringement against Alnylam means its four LNP patents cannot be enforced against Pfizer’s accused products in this action. The judgment is expressly described as final and appealable, so Alnylam retains the right to appeal to the Federal Circuit, particularly on the underlying claim construction of ‘cationic lipid.’ Whether an appeal is commercially viable will depend on the strength of the claim construction record and Alnylam’s broader licensing strategy.
Noninfringement — appeal eligiblePfizer clears noninfringement — validity fight still open
Pfizer and Pharmacia & Upjohn secured a complete noninfringement judgment on all asserted claims without a trial. Critically, the dismissal of their counterclaims without prejudice means invalidity arguments were not adjudicated — Pfizer could still pursue IPR petitions or assert invalidity in future proceedings if Alnylam reasserts these patents. This outcome reduces near-term commercial exposure while preserving strategic optionality.
Noninfringement confirmedLNP patent landscape remains contested after this judgment
The ruling does not invalidate Alnylam’s four LNP delivery patents — it solely addresses Pfizer’s products. Competitors and licensees in the LNP space should note that the ‘cationic lipid’ claim construction remains outcome-determinative. Companies developing ionizable or biodegradable lipid delivery systems should assess whether their formulations map onto the construed claim scope. The unresolved counterclaims mean validity challenges to these patents remain a live risk in the sector.
LNP IP risk not eliminatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Alnylam Pharmaceuticals, Inc. | Company | RNAi therapeutics innovator — holder of US11590229B2 and three related LNP delivery patentsSearch in Eureka ↗ |
| Defendant | Pfizer, Inc. | Company | Global pharmaceutical manufacturer and LNP-based therapeutic developerSearch in Eureka ↗ |
| Co-Defendant | Pharmacia & Upjohn Company, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Anisa K. Noorassa | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Bhanu K. Sadasivan | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ethan Haller Townsend | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ian B. Brooks | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mandy H. Kim | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Chapin Columbia | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sarah J. Fischer | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Timothy M. Dunker | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William G. Gaede , III | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McDermott Will & Emery LLP | Law Firm | Representing Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Alan Richard Silverstein | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Arthur G. Connolly | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Dan Constantinescu | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael W. Johnson | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Sara T. Horton | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant law firm | Connolly Gallagher LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The final judgment is notable for its stipulated structure: Alnylam’s decision not to oppose Pfizer’s summary judgment motion, following denial of its claim construction motion, effectively conceded noninfringement on the record. The court’s language — ‘final, appealable judgment’ — is deliberate, signaling that this is not a procedural dismissal but a merits determination. The without-prejudice dismissal of counterclaims means patent validity was never adjudicated, narrowing the precedential impact to noninfringement under the disputed ‘cationic lipid’ construction specifically.
US11590229B2 — Biodegradable lipids for lipid nanoparticle drug delivery
The four asserted patents — US11590229B2, US11633479B, US11612657B2, and US11633480B2 — share a common technical focus on biodegradable lipid compositions used to construct lipid nanoparticles (LNPs) capable of delivering nucleic acid or other active agents in vivo. All four were filed as continuations in the US17/651xxx application family in early 2022, suggesting they represent a coordinated patent portfolio built around a core LNP lipid chemistry disclosure. LNP technology is foundational to mRNA therapeutics and RNAi drugs, making these patents strategically significant across multiple therapeutic modalities.
Alnylam is a pioneer in RNAi therapeutics and has historically used LNP delivery systems as a core enabler of its drug pipeline. Asserting these patents against Pfizer — whose COVID-19 vaccine co-developed with BioNTech relies on LNP formulations — represents one of the highest-profile LNP IP enforcement actions in biopharma. The outcome of this case, resolving on ‘cationic lipid’ claim construction rather than on the underlying chemistry, leaves the commercial scope of these patents unresolved for third parties not party to this judgment.
Should you run an FTO against US11590229B2 and the Alnylam LNP patent family?
Any company developing LNP-based delivery systems — particularly those using ionizable or biodegradable lipids for mRNA, siRNA, or other nucleic acid therapeutics — should treat Alnylam’s US17/651xxx patent family as a priority FTO target. The noninfringement ruling here was Pfizer-specific and dependent on a particular claim construction; it does not clear third-party developers. The four patents remain in force, and Alnylam retains both enforcement and appeal rights.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map their specific lipid formulations against the claim language of US11590229B2 and related patents, flagging potential overlap at the compound, composition, and method levels. Eureka’s claim construction analytics can also surface how courts and the USPTO have interpreted key terms like ‘cationic lipid’ and ‘biodegradable’ in related proceedings, giving product teams a sharper risk picture before advancing formulations into development.
Run a freedom-to-operate analysis on US11590229B2 to assess your product’s exposure
Run FTO in Eureka →Similar LNP and lipid delivery patent infringement cases in Delaware
Explore related lipid nanoparticle and nucleic acid delivery patent disputes litigated in the District of Delaware and related biopharma IP proceedings.
What this case signals for the lipid nanoparticle IP landscape
Claim construction of ‘cationic lipid’ decided this case. The LNP patent landscape remains highly contested for biopharma developers.
Claim construction is the battleground in LNP patent disputes
The entire case pivoted on how ‘cationic lipid’ is construed. When the court denied Alnylam’s motion to resolve that construction, the infringement case collapsed. For LNP patent holders and challengers alike, investing early in rigorous claim construction strategy — particularly on lipid chemistry terminology — is decisive, not peripheral.
Dismissal without prejudice preserves Pfizer’s IPR threat
Defendants’ counterclaims were dismissed without prejudice, meaning Pfizer could still file inter partes review petitions against Alnylam’s LNP patents. Patent holders should treat this outcome as a litigation ceasefire, not a final resolution. Monitoring for future USPTO filings by Pfizer or its affiliates is advisable for Alnylam and its licensees.
Alnylam v Pfizer — key questions answered
The court entered final judgment of noninfringement on all asserted claims of Alnylam’s four LNP patents (US11590229B2, US11633479B, US11612657B2, US11633480B2) in favor of Pfizer. The judgment followed Alnylam’s non-opposition to Pfizer’s summary judgment motion on ‘cationic lipid’ limitations, after the court denied Alnylam’s claim construction motion. Defendants’ counterclaims were dismissed without prejudice.
After the court denied Alnylam’s O2 Micro motion seeking resolution of a claim construction dispute over ‘cationic lipid’ limitations on April 28, 2025, Alnylam filed a notice of non-opposition to Pfizer’s pending summary judgment motion on those same limitations. The denial of the claim construction motion appears to have removed the basis for Alnylam to contest noninfringement, leading to a stipulated final judgment. The precise strategic reasoning is not fully disclosed in the public record.
Yes. The final judgment addresses only noninfringement by Pfizer’s specific accused products — it does not adjudicate validity. Pfizer’s counterclaims challenging validity were dismissed without prejudice, meaning the patents remain in force and enforceable against other parties. Alnylam retains the right to assert these patents in other proceedings.
The case outcome suggests that how ‘cationic lipid’ is defined in Alnylam’s asserted patents was determinative of the noninfringement finding. While the specific construction is not detailed in the public judgment, companies using ionizable or biodegradable lipid formulations that differ chemically from traditional cationic lipids may have a relevant non-infringement argument. Independent FTO analysis is recommended for any LNP developer designing around these patents.
Yes. The final judgment order expressly states it is ‘a final, appealable judgment,’ which preserves Alnylam’s right to appeal to the US Court of Appeals for the Federal Circuit. An appeal would likely focus on the underlying claim construction of ‘cationic lipid’ and the denial of Alnylam’s O2 Micro motion. Federal Circuit review of claim construction is de novo, meaning the appellate court applies no deference to the district court’s construction.
PatSnap Eureka searches patents and litigation data to answer instantly.